These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26020402)

  • 1. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Zhu X; Zhang X; Fu Y
    Medicine (Baltimore); 2015 May; 94(21):e909. PubMed ID: 26020402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.
    Zhu X; Ye H; Fu Y
    Medicine (Baltimore); 2016 Jul; 95(28):e4193. PubMed ID: 27428219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
    Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Different Progestins in Women With Advanced Endometriosis Undergoing Controlled Ovarian Hyperstimulation for
    Guo H; Li J; Shen X; Cong Y; Wang Y; Wu L; Li B; Gao H; Ma M; Zhang W; Mao X; Fu Y; Lyu Q; Chai W; Kuang Y
    Front Endocrinol (Lausanne); 2020; 11():129. PubMed ID: 32265834
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Medicine (Baltimore); 2017 Aug; 96(32):e7540. PubMed ID: 28796038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
    Branigan EF; Estes MA
    Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
    Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
    Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
    BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different progestin-primed ovarian stimulation protocols in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: an analysis of 1188 cycles.
    Guo YC; Chen PY; Li TT; Jia L; Sun P; Zhu WS; Deng CC; Fang C; Liang XY
    Arch Gynecol Obstet; 2019 Apr; 299(4):1201-1212. PubMed ID: 30852654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology.
    Iwami N; Kawamata M; Ozawa N; Yamamoto T; Watanabe E; Moriwaka O; Kamiya H
    Arch Gynecol Obstet; 2018 Sep; 298(3):663-671. PubMed ID: 30069600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
    Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
    Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing
    Zhu X; Ye H; Ye J; Fu Y
    Ann Transl Med; 2021 Mar; 9(5):387. PubMed ID: 33842608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study.
    Huang J; Xie Q; Lin J; Lu X; Zhu J; Gao H; Cai R; Kuang Y
    Drug Des Devel Ther; 2019; 13():4461-4470. PubMed ID: 32099323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study.
    Zhang Y; Xu Y; Yu J; Wang X; Xue Q; Shang J; Yang X; Shan X
    J Ovarian Res; 2023 Jun; 16(1):119. PubMed ID: 37370146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.